antibody

Platelet Derived Growth Factor Receptor, Type B, phosphorylated (Tyr740) (PDGFRb)

P4258-20B

100 ul

monoclonal

domestic rabbit

nonconjugated

phosphorylated

5i127(32A9)

Platelet Derived Growth Factor Receptor, Type B, phosphorylated (Tyr740) (PDGFRb)

rabbit

Mab

Phosphorylated

Antibodies

100 ul

5i127(32A9)

IgG

The proteins of the PDGF family consist of several disulfide-bonded dimeric isoforms: PDGFAA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD, which bind in a distinct pattern to two highly related RTKs: PDGFR-a and PDGFR-b. PDGFR-a and PDGFR-b show 85% and 75% identity between the two intracellular kinase domains, but the kinase insert and carboxy terminal tail regions display only 27% and 28% identity. PDGFR-a binds all PDGF isoforms except PDGF-D, whereas PDGFR-b can only affiliate with PDGF-B and D 1). PDGFR-a and PDGFR-b not only form homo- and heterodimers, but also dimerize with EGFR, which can be stimulated by PDGF (2). The total number and the ratio of receptor subunits expressed varies between cell types, possibly accounting for the variable responsiveness of different cell types to PDGF (3). Ligand binding induces receptor dimerization and autophosphorylation, allowing binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules including Grb2, Src, GAP, PI3 kinase, PLCg and Nck. A number of different signaling pathways are thereby initiated leading to cell growth, actin reorganization, migration and differentiation (4). Tyr751 in the kinase-insert region of PDGFR-b is the docking site for PI3 kinase 5). Phosphorylated pentapeptides derived from Tyr751 of PDGFR-b (pTyr751-Val-Pro-Met-Leu) inhibit the association of the carboxy-terminal SH2 domain of the p85 subunit of PI3 kinase with PDGFR-b (6). Tyr740 is also required for PDGFR-b-mediated PI-3 kinase activation 7). Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1:1000 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot. Store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Hu Mo

Synthetic phosphopeptide corresponding to residues surrounding Tyr740 of human PDGF receptor b.

Detects endogenous levels of human PDGF receptor b only when phosphorylated at tyrosine 740. The antibody may crossreact with activated PDGF receptor-a. Species Crossreactivity: mouse

Purified

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.

100ul (10 Western mini-blots)

Product Type: Mab Isotype: IgG Clone No: 5i127(32A9) Host: rabbit Source: human Concentration: 100ul (10 Western mini-blots) Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. Purity: Purified Immunogen: Synthetic phosphopeptide corresponding to residues surrounding Tyr740 of human PDGF receptor b. Specificity: Detects endogenous levels of human PDGF receptor b only when phosphorylated at tyrosine 740. The antibody may crossreact with activated PDGF receptor-a. Species Crossreactivity: mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

WB

-20°C

(1) Deuel, T.F. et al. (1988) Biofactors 1, 213–217. (2) Betsholtz, C. et al. (2001) Bioessays 23, 494–507. (3) Coughlin, S.R. et al. (1988) Prog. Clin. Biol. Res. 266, 39–45. (4) Ostman, A. and Heldin, C.H. (2001) Adv. Cancer Res. 80, 1–38. (5) Panayotou, G. et al. (1992) EMBO J. 11, 4261–4272. (6) Ramalingam, K. et al. (1995) Bioorg. Med. Chem. 3, 1263–1272. (7) Kashishian, A. et al. (1992) EMBO J. 11, 1373–1382. General References: 1. Spieker-Polet H, et al. Proc Natl Acad Sci. 1995 Sep 26;92(20):9348-52. 2. Liguori MJ, et al. Hybridoma. 2001 Jun; 20(3):189-98. 3. G.Cano1, F. Milanezi2, D. Leitao2,3, S. Ricardo2, M.J. Brito1, F. C. Schmitt2-3 1Garcia da Orta Hospital, Almada, Portugal,2 Inst. Molec. Pathology and Immunology of Porto University, Portugal,3 Medical Faculty of Porto university, Portugal Diagn Cytopathol, 2003 Oct; 29(4): 207 -11. 4. L.K. Diaz* and N.Sneige *Department of Pathology,Northwestern University, Chicago,+ Department of Pathology, University of Texas, Huston, Adv Anat Pathol,2005; 12(1), 10-19. 5. Z. Huang1, W. Zhu2, G. Szekeres3, H. Xia1 1Spring Bioscience Corp, Fremont,CA, 2 Epitomics Inc, Burlingame,CA, , 4Histopathology Ltd, Hungary, Appl Immunohistochem Mol Morphol. 2005; 13 (1): 91-95 6. S. Rossi1, E. Orvieto1, S.Chinellato1, A. Furlanetto1, L.Laurino1, F. Facchetti2, AP Dei Tos 2 1Department of Pathology, 2Treviso, Italy; *Brescia, University School of Medicine, Brescia, Italy., Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 361A 7. M. Blechner, E. Ballesteros, D. Mandich, D. Stevens, R. Cartun, Hartford Hospital, Hartford, CT. Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 241A 8. W. Cheuk, K.O.Y. Wong, C.S.C. Wong and J.K.C. Chan, Department of Pathology, Queen Elizabeth Hospital, Hong Kong, Am J Surg Path, 2004; 28 (6): 801-807. 9. G.B. Budd, E. Tso, B. Yoder, T. Choueiri, P. Elson, S. Tarr, M. Skacel, R. Tubbs, A. Dawson, D. Hicks, Cleveland Clinic Foundation, Cleveland, OH, Abstract presented at ASCO Annual meeting, June 2004, New Orleans 10. S. M. Tarr, S. Short, K. Hansen, T. Morken, H. Xia, E. Downs-Kelly, R. R. Tubbs, D. G. Hicks, Department of Pathology and Laboratory Medicine. The Cleveland Clinic Foundation, Cleveland, Ohio. Lab Vision Corp., Fremont, Ca., Spring Bioscience Corp, Fremont ,CA, Abstract presented at Association for Molecular Pathology meeting, Los Angeles, 2004 11. A.M. Gown, T.S. Barry, P. Kandalaft, L.C. Goldstein, C.C. Tse and D.O. Treaba, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 35A 12. D.O. Treaba, A.W. Hing, L.C. Goldstein, T.S. Barry, P. Kandalaft, C.B. Gilks, T.O. Nielsen and A.M. Gown, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, USA Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 53A 13. S. Rossi1, L. Laurino1, A. Furlanetto1, S.Chinellato1, E. Orvieto1, F. Canal1, F. Facchetti2, A.P. Dei Tos1 1 Depart. Pathology, Hospital of Treviso, Italy, 2 Brescia University School of Medicine, Brescia, Italy, Am J Clin Pathol, 2005, Aug;124(2):295-302

https://usbio-images.r.worldssl.net/prodimages/24/P4258-20B_1.jpg